Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given their signed consent to participate
- People who have a clinically significant cataract (a cataract that is affecting vision or eye health)
- People who are able to attend follow-up visits over a 12-month period
- People who have mild to moderate exfoliation glaucoma, as defined by European Glaucoma Society guidelines
- People whose glaucoma is either stable (eye pressure is within their personal target range) or unstable (eye pressure is above their personal target range), while using their current glaucoma medications
- People whose target eye pressure is 16 mmHg or higher
- People who are able to communicate in Finnish, Swedish, or English
Who may not be able to join:
- People whose doctors have set a target eye pressure below 16 mmHg due to advanced glaucoma
- People whose eye pressure before enrolment is 30 mmHg or higher and who are already using three or more glaucoma medications
- People with a closed drainage angle in the eye
- People with a condition where the eye's drainage angle did not develop normally
- People with a significant corneal (front of the eye) disease or condition that could interfere with the trial
- People who are unable to use eye drop medications
- People whose central corneal thickness is less than 480 micrometres or more than 620 micrometres (a measurement taken during an eye exam)
- People with certain active eye conditions, including uveitis, macular swelling, a specific type of age-related macular degeneration, advanced diabetic eye disease, eye tumours, a history of injections into the eye, or a displaced artificial lens (confirm with trial site)
- People who have previously had eye surgery, laser vision correction surgery, or a procedure to reduce fluid production in the eye
- People who have had two or more previous selective laser trabeculoplasty (SLT) or similar laser treatments to the eye's drainage system
- People who are unable to participate due to another medical condition
- People who are currently taking part in another clinical trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mika Harju, MD, prof., Helsinki University Central Hospital
Phone: +358503608589
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Group I: Change in the number of IOP lowering medications compared to baseline; Group II: Change in the IOP compared to baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.